PL2569009T3 - Chimery ospa i ich zastosowanie do szczepień - Google Patents

Chimery ospa i ich zastosowanie do szczepień

Info

Publication number
PL2569009T3
PL2569009T3 PL11722243T PL11722243T PL2569009T3 PL 2569009 T3 PL2569009 T3 PL 2569009T3 PL 11722243 T PL11722243 T PL 11722243T PL 11722243 T PL11722243 T PL 11722243T PL 2569009 T3 PL2569009 T3 PL 2569009T3
Authority
PL
Poland
Prior art keywords
vaccines
ospa chimeras
ospa
chimeras
Prior art date
Application number
PL11722243T
Other languages
English (en)
Inventor
Brian A. Crowe
Ian Livey
Maria O'rourke
Michael Schwendinger
Original Assignee
Baxalta Incorporated
Baxalta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Incorporated, Baxalta GmbH filed Critical Baxalta Incorporated
Publication of PL2569009T3 publication Critical patent/PL2569009T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL11722243T 2010-05-14 2011-05-13 Chimery ospa i ich zastosowanie do szczepień PL2569009T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33490110P 2010-05-14 2010-05-14
EP11722243.0A EP2569009B1 (en) 2010-05-14 2011-05-13 Ospa chimeras and use thereof in vaccines
PCT/US2011/036525 WO2011143617A1 (en) 2010-05-14 2011-05-13 Chimeric ospa genes, proteins, and methods of use thereof

Publications (1)

Publication Number Publication Date
PL2569009T3 true PL2569009T3 (pl) 2020-06-15

Family

ID=44121257

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11722243T PL2569009T3 (pl) 2010-05-14 2011-05-13 Chimery ospa i ich zastosowanie do szczepień
PL11720967T PL2569008T3 (pl) 2010-05-14 2011-05-13 Chimery ospa i ich zastosowanie w szczepionkach

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL11720967T PL2569008T3 (pl) 2010-05-14 2011-05-13 Chimery ospa i ich zastosowanie w szczepionkach

Country Status (13)

Country Link
US (6) US8623375B2 (pl)
EP (4) EP2569008B1 (pl)
JP (6) JP6227407B2 (pl)
KR (7) KR102222869B1 (pl)
CN (3) CN103118701B (pl)
AU (2) AU2011252844B2 (pl)
BR (2) BR112012029058B1 (pl)
CA (2) CA2798331C (pl)
MX (2) MX340739B (pl)
PL (2) PL2569009T3 (pl)
RU (2) RU2636455C2 (pl)
SI (2) SI2569009T1 (pl)
WO (2) WO2011143623A1 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2798331C (en) * 2010-05-14 2022-03-15 Baxter International Inc. Ospa chimeras and use thereof in vaccines
US20120124496A1 (en) 2010-10-20 2012-05-17 Mark Rose Geographic volume analytics apparatuses, methods and systems
US10438176B2 (en) 2011-07-17 2019-10-08 Visa International Service Association Multiple merchant payment processor platform apparatuses, methods and systems
US10318941B2 (en) 2011-12-13 2019-06-11 Visa International Service Association Payment platform interface widget generation apparatuses, methods and systems
US10096022B2 (en) * 2011-12-13 2018-10-09 Visa International Service Association Dynamic widget generator apparatuses, methods and systems
US8986704B2 (en) * 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
KR20150038380A (ko) * 2012-07-27 2015-04-08 백스터 인터내셔널 인코포레이티드 키메라 ospa 분자를 포함하는 조성물 및 이의 사용 방법
PL223175B1 (pl) 2012-10-22 2016-10-31 Inst Chemii Bioorganicznej Polskiej Akademii Nauk Szczepionka przeciw boreliozie, konstrukt genetyczny, rekombinowane białko, sposób otrzymywania konstruktu genetycznego, sposób otrzymywania szczepionki, sposób otrzymywania rekombinowanych białek, zastosowanie rekombinowanych białek do wytwarzania szczepionki przeciwko boreliozie
WO2015041710A1 (en) * 2013-09-23 2015-03-26 Ventria Bioscience, Inc. Ospa fusion protein for vaccination against lyme disease
WO2015104396A1 (en) * 2014-01-09 2015-07-16 Valneva Austria Gmbh Mutant fragments of ospa and methods and uses relating thereto
CZ2014320A3 (cs) * 2014-05-09 2015-11-18 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
WO2016025331A1 (en) 2014-08-11 2016-02-18 University Of Massachusetts Anti-ospa antibodies and methods of use
US11216468B2 (en) 2015-02-08 2022-01-04 Visa International Service Association Converged merchant processing apparatuses, methods and systems
EP3266236B1 (en) * 2015-08-14 2019-03-06 Telefonaktiebolaget LM Ericsson (PUBL) A node and method for managing a packet data network connection
US20190284261A1 (en) * 2016-11-07 2019-09-19 The Trustees Of The University Of Pennsylvania Dna antibody constructs for use against lyme disease
WO2018189372A1 (en) * 2017-04-13 2018-10-18 Valneva Austria Gmbh Multivalent ospa polypeptides and methods and uses relating thereto
WO2019195316A1 (en) 2018-04-03 2019-10-10 Sanofi Ferritin proteins
JP2021519599A (ja) * 2018-04-03 2021-08-12 サノフイＳａｎｏｆｉ 抗原性ｏｓｐａポリペプチド
CN112512566A (zh) 2018-04-03 2021-03-16 赛诺菲 抗原性爱泼斯坦-巴尔病毒多肽
CN110483624B (zh) * 2019-08-22 2021-02-09 中国疾病预防控制中心传染病预防控制所 伽氏疏螺旋体OspA蛋白C端肽段及其应用
CN111196842A (zh) * 2020-01-09 2020-05-26 济南大学 一种外膜转运通道蛋白的非跨膜结构域的表达纯化方法
WO2021205022A1 (en) 2020-04-09 2021-10-14 Valneva Austria Gmbh Improved methods of producing a lipidated protein
WO2022261050A1 (en) * 2021-06-07 2022-12-15 The University Of Massachusetts Apparatus and method for continuous production of rna
WO2023170680A1 (en) 2022-03-08 2023-09-14 Equashield Medical Ltd Fluid transfer station in a robotic pharmaceutical preparation system

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4877612A (en) 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DE3775783D1 (de) 1986-01-14 1992-02-20 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4830885A (en) 1987-06-08 1989-05-16 Allied-Signal Inc. Chlorine-resistant semipermeable membranes
US5777095A (en) 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US7094391B1 (en) 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
US6143872A (en) * 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
DE68925966T2 (de) 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1992000055A1 (en) 1990-06-15 1992-01-09 Yale University Compositions and methods for the prevention and diagnosis of lyme disease
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP3215109B2 (ja) 1991-02-15 2001-10-02 ユーエイビー リサーチ ファウンデーション 肺炎球菌タンパクの構造遺伝子
CA2115554A1 (en) 1991-08-15 1993-03-04 Yves Lobet Osp a proteins of borrelia burgdorferi subgroups, encoding genes and vaccines
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
WO1995012676A1 (en) * 1993-11-01 1995-05-11 Associated Universities, Inc. Chimeric proteins comprising borrelia polypeptides: uses therefor
CA2244110A1 (en) 1996-02-12 1997-08-14 Cobra Therapeutics Limited Novel methods of vaccination and vaccines thereof comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
US6368603B1 (en) * 1997-03-05 2002-04-09 Merial Limited Lyme combination compositions and uses
WO1999000413A1 (en) 1997-06-30 1999-01-07 The Administrators Of The Tulane Educational Fund Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
GB9726555D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
GB9811219D0 (en) 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel process
EP1311682B1 (en) 2000-08-18 2007-12-12 Research Foundation Of State University Of New York Recombinant constructs of borrelia burgdorferi
AU2001285049A1 (en) 2000-08-18 2002-03-04 Brookhaven Sciences Associates, Llc Altered ospa of borrelia burgdorferi
EP1939294A1 (en) * 2000-08-18 2008-07-02 Research Foundation Of State University Of New York Recombinant constructs of borrelia burgdorferi
RU2385323C2 (ru) 2003-04-02 2010-03-27 ДЗЕ ГАВЕРМЕНТ ОФ ДЗЕ ЮНАЙТЕД СТЕЙТС ОФ АМЕРИКА Эз репрезентед бай ДЗЕ СЕКРЕТЭРИ, ДЕПАРТМЕНТ ОФ ХЕЛТ ЭНД ХЬЮМЭН СЕРВИСИЗ Холестеринсодержащие соединения и их применение в качестве иммуногенов против borrelia burgdorferi
KR20060019515A (ko) * 2003-04-16 2006-03-03 와이어쓰 홀딩스 코포레이션 수막구균 질환의 예방 및 치료용 신규 면역원성 조성물
PL1730175T3 (pl) * 2004-03-24 2010-09-30 Merck Sharp & Dohme Optymalizowana ekspresja L1 HPV 52 w drożdżach
WO2006014292A2 (en) 2004-07-02 2006-02-09 Dattwyler Raymond J Oral vaccine for borrelia
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
JP5390189B2 (ja) * 2005-11-29 2014-01-15 ヴァージニア コモンウェルス ユニバーシティ 多価キメラｏｓｐｃワクシノーゲンおよび診断用抗原
RU2008126239A (ru) * 2005-11-29 2010-01-10 Вирджиния Коммонвелт Юниверсити (Us) Поливалентный химерный вакциноген и диагностический антиген ospc
CA2661224A1 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
JP5443175B2 (ja) 2007-02-22 2014-03-19 バクスター・インターナショナル・インコーポレイテッド 疎水性タンパク質を精製する方法
PT2167121E (pt) * 2007-06-26 2015-12-02 Glaxosmithkline Biolog Sa Vacina compreendendo conjugados de polissacáridos capsulares de streptococcus pneumoniae
MX2010007461A (es) * 2008-01-11 2010-10-20 VGX Pharmaceuticals LLC Nuevas vacunas contra multiples subtipos del virus del dengue.
EP2274616A1 (en) 2008-04-22 2011-01-19 The Research Foundation of State University of New York Borrelia burgdorferi cell envelope protein array
EP2283031B1 (en) 2008-05-02 2017-04-12 Virginia Commonwealth University Lyme disease vaccine
CA2798331C (en) 2010-05-14 2022-03-15 Baxter International Inc. Ospa chimeras and use thereof in vaccines
KR20150038380A (ko) * 2012-07-27 2015-04-08 백스터 인터내셔널 인코포레이티드 키메라 ospa 분자를 포함하는 조성물 및 이의 사용 방법

Also Published As

Publication number Publication date
BR112012029058A2 (pt) 2020-06-23
RU2583289C2 (ru) 2016-05-10
CN103108652A (zh) 2013-05-15
KR20200084062A (ko) 2020-07-09
US9895434B2 (en) 2018-02-20
JP6227407B2 (ja) 2017-11-08
JP6965417B2 (ja) 2021-11-10
CN103108652B (zh) 2016-05-11
KR102222869B1 (ko) 2021-03-04
BR112012027315B1 (pt) 2021-08-17
US9334311B2 (en) 2016-05-10
KR102230562B1 (ko) 2021-03-22
US20180296656A1 (en) 2018-10-18
CN107641151A (zh) 2018-01-30
JP2013529078A (ja) 2013-07-18
US20140141029A1 (en) 2014-05-22
CA2798331A1 (en) 2011-11-17
RU2017138652A3 (pl) 2021-03-15
EP3705133A3 (en) 2021-01-06
KR102085465B1 (ko) 2020-03-05
RU2012153972A (ru) 2014-06-20
CN107641151B (zh) 2021-10-01
EP3705133A2 (en) 2020-09-09
AU2011252850A1 (en) 2012-11-29
US20120020973A1 (en) 2012-01-26
SI2569008T1 (sl) 2020-02-28
JP6030052B2 (ja) 2016-11-24
CA2798331C (en) 2022-03-15
BR112012029058B1 (pt) 2022-03-29
EP2569009A1 (en) 2013-03-20
AU2011252844A1 (en) 2012-11-29
JP2018150386A (ja) 2018-09-27
JP2016171816A (ja) 2016-09-29
JP2020178719A (ja) 2020-11-05
CA2799181A1 (en) 2011-11-17
PL2569008T3 (pl) 2021-04-19
SI2569009T1 (sl) 2020-02-28
JP2013529077A (ja) 2013-07-18
KR20190027955A (ko) 2019-03-15
US8623376B2 (en) 2014-01-07
US9303073B2 (en) 2016-04-05
EP2569008B1 (en) 2019-12-25
MX2012013264A (es) 2014-12-05
WO2011143623A1 (en) 2011-11-17
AU2011252850B2 (en) 2016-03-17
KR20200024354A (ko) 2020-03-06
KR20180031814A (ko) 2018-03-28
MX340739B (es) 2016-07-22
EP3650041A1 (en) 2020-05-13
AU2011252844B2 (en) 2014-07-03
RU2017138652A (ru) 2019-02-11
EP2569009B1 (en) 2019-10-09
KR102130584B1 (ko) 2020-07-07
JP2016168057A (ja) 2016-09-23
RU2012153752A (ru) 2014-06-20
KR20130062954A (ko) 2013-06-13
US11305000B2 (en) 2022-04-19
US8623375B2 (en) 2014-01-07
BR112012027315A2 (pt) 2016-11-16
EP2569008A1 (en) 2013-03-20
US20160235830A1 (en) 2016-08-18
WO2011143617A1 (en) 2011-11-17
MX2012013261A (es) 2013-04-19
US20110293652A1 (en) 2011-12-01
KR20180082633A (ko) 2018-07-18
CA2799181C (en) 2023-10-24
CN103118701B (zh) 2017-10-24
RU2636455C2 (ru) 2017-11-23
US20140141030A1 (en) 2014-05-22
BR112012027315A8 (pt) 2020-09-01
CN103118701A (zh) 2013-05-22
KR20130133120A (ko) 2013-12-06
MX348113B (es) 2017-05-29

Similar Documents

Publication Publication Date Title
SI2569008T1 (sl) Himere OSPA in njihova uporaba v cepivih
HUS2100032I1 (hu) Helyettesített 5-fluor-1H-pirazolopiridin-származékok és alkalmazásuk
HK1187049A1 (en) Bisaryl-bonded aryltriazolones and use thereof
HK1192879A1 (zh) 取代的 -苄基環烷基羧酸及其用途
IL215389A0 (en) Pneumococcal vaccine and uses thereof
HK1184488A1 (en) Human facilitating cells and uses thereof
ZA201208173B (en) Peptices and their use
EP2536293A4 (en) METHODS AND COMPOSITIONS FOR USE IN AQUACULTURE
ZA201302168B (en) Electrode unit for use in a fryer and fryer comprising a said electrode unit
PT2521445T (pt) Formulação e utilização da mesma
PT2563806E (pt) Leucolectinas humanas e suas utilizações
GB201008286D0 (en) Device and use
GB201005441D0 (en) Improvements in wheelchairs
GB201001170D0 (en) Novel peptides and their use in therepy and diagnosis
GB201021105D0 (en) Improvements in and relating to parathas